WELCOME TO OUR MAAT PHARMA WEBSITE!
MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.
MaaT Pharma To Release First in Patients Data At The 2017 ASH Meeting On Autologous Fecal Microbiota Transfer And Restoration Of Microbiota Diversity
The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the...
Hervé Affagard live on Europe1 Label Entreprise talking about the company, our future and perspective, but mostly describing how we restore gut microbiota with Fecal Microbiota Transfer.